Pomerantz Law Firm Launches Investigation for Evolus Investors Following FDA Warning

Investigation of Evolus, Inc.

Recently, Pomerantz Law Firm has initiated an investigation targeting investors of Evolus, Inc. (NASDAQ: EOLS). This follows significant developments involving the company's marketing practices related to its popular wrinkle treatment, Jeuveau.

Background of the Case

Evolus, a company specializing in aesthetic treatments, has come under scrutiny after the FDA issued a warning regarding its promotional activities. On October 2, 2026, the FDA disclosed that an Instagram post promoting Jeuveau was misleading. The post allegedly compared the injectable treatment to everyday beauty products while downplaying important safety information. This prompted an immediate drop in Evolus's stock price, with a decrease of 7.15%, closing at $7.14 per share.

Nature of the Allegations

The investigation by Pomerantz aims to determine whether Evolus and its officers breached securities laws or engaged in other unlawful business practices. Specifically, the FDA criticized the company for making exaggerated claims about Jeuveau's effectiveness, suggesting it could eliminate frown lines completely and deliver results in as little as two days. Moreover, the FDA pointed out that the post did not sufficiently highlight critical safety warnings concerning the potential for distant spread of toxin effects.

The Role of Pomerantz Law Firm

Recognized as a leading firm in corporate and securities litigation, Pomerantz has a long-standing reputation for advocating on behalf of investors against companies accused of fraud and misconduct. Founded over 85 years ago, Pomerantz was established by Abraham L. Pomerantz, a pioneer in the realm of class action lawsuits, and has since successfully recovered substantial damages for its clients.

As part of its investigation, Pomerantz is encouraging investors affected by the recent stock decline linked to the FDA's warning to contact them. This initiative represents an ongoing commitment to protecting shareholder interests and holding companies accountable for their marketing practices.

What’s Next?

Investors who believe they may have been impacted by the developments surrounding Evolus are urged to reach out to Pomerantz Law Firm. The firm is prepared to assist clients in understanding their rights and potential avenues for recovery.

For inquiries, investors can contact Danielle Peyton at Pomerantz LLP via email at [email protected] or call 646-581-9980, ext. 7980.

Conclusion

As this situation unfolds, it highlights the importance of transparency in marketing, especially in the pharmaceuticals and cosmetic industries. Investors are advised to stay informed and consider their options moving forward. Pomerantz's investigation could serve as a critical step in addressing any wrongdoing by Evolus and ensuring investors' rights are upheld.